Home › Companies › Beam Therapeutics Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Beam Therapeutics Inc.’s Form 8-K, filed June 8, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 3, 2026: 5 items on Beam Therapeutics Inc.’s Form 8-K, filed June 8, 2026: 3 elected · 2 approved.
Notable dissent: 1 director (10.6% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Beam Therapeutics Inc. in the interactive database Compare manager voting policies
These tallies are Beam Therapeutics Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 8, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: John Evans | 71,684,417 | 864,042 | 256,889 | -- | 13,419,659 | 99% | Elected | — |
| Elect Director: John Maraganore, Ph.D. | 64,846,080 | 7,701,591 | 257,677 | -- | 13,419,659 | 89% | Elected | — |
| Elect Director: Christi Shaw | 65,652,959 | 6,893,102 | 259,287 | -- | 13,419,659 | 90% | Elected | — |
| 2. Appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2026 | 85,754,272 | 165,746 | 304,989 | -- | -- | 99.8% | Approved | — |
| 3. Compensation of the Company's named executive officers | 71,546,749 | 985,066 | 273,533 | -- | 13,419,659 | 99% | Approved | — |
Source: Beam Therapeutics Inc., Form 8-K, filed with the SEC on June 8, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
288 asset managers disclosed a vote on at least one Beam Therapeutics Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Description as filed by funds: Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2029: Christi Shaw
Beam Therapeutics Inc.’s own tally for this item (“Elect Director: Christi Shaw”): 65,652,959 for, 6,893,102 against, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – The following nominees were elected as Class III directors to serve on the Company's board of directors until the Company's 2029 annual meeting of stockholders, and until his or her successor has been duly elected and qualified, based on the following votes:”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 68 asset managers below reported 32,535,732 for, 906,587 against, 29,911 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARK ETF Trust | 10,432,026 | 0 | 0 | 0 | For |
| Vanguard | 8,899,217 | 16 | 0 | 0 | For |
| Fidelity | 5,159,735 | 0 | 0 | 0 | For |
| BlackRock | 2,218,373 | 0 | 0 | 0 | For |
| State Street | 1,849,201 | 2,166 | 0 | 0 | For |
| T. Rowe Price | 1,263,414 | 0 | 0 | 0 | For |
| Charles Schwab | 808,304 | 0 | 0 | 0 | For |
| ARK Venture Fund | 337,310 | 0 | 0 | 0 | For |
| Equitable | 178,015 | 69,200 | 0 | 0 | Mixed |
| AMERICAN BEACON FUNDS | 223,757 | 0 | 0 | 0 | For |
| TIAA | 221,207 | 0 | 0 | 0 | For |
| American Century | 0 | 168,022 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 155,367 | 0 | 0 | 0 | For |
| Brighthouse | 124,164 | 17,701 | 0 | 0 | Mixed |
| First Trust | 0 | 135,021 | 0 | 0 | Against |
| JPMorgan | 128,586 | 0 | 0 | 0 | For |
| ProShares | 0 | 95,136 | 0 | 0 | Against |
| Dimensional | 0 | 92,406 | 0 | 0 | Against |
| Lincoln Financial | 71,834 | 16,344 | 0 | 0 | Mixed |
| AIG/SunAmerica | 0 | 69,869 | 0 | 0 | Against |
| Russell Investments | 65,283 | 0 | 0 | 0 | For |
| Transamerica | 60,019 | 0 | 0 | 0 | For |
| Global X | 55,500 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 0 | 50,397 | 0 | 0 | Against |
| Northern Trust | 44,362 | 0 | 0 | 0 | For |
Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2029: John Evans
Beam Therapeutics Inc.’s own tally for this item (“Elect Director: John Evans”): 71,684,417 for, 864,042 against, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – The following nominees were elected as Class III directors to serve on the Company's board of directors until the Company's 2029 annual meeting of stockholders, and until his or her successor has been duly elected and qualified, based on the following votes:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 68 asset managers below reported 33,233,427 for, 208,890 against, 29,911 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARK ETF Trust | 10,432,026 | 0 | 0 | 0 | For |
| Vanguard | 8,890,913 | 8,318 | 0 | 0 | For |
| Fidelity | 5,159,735 | 0 | 0 | 0 | For |
| BlackRock | 2,218,373 | 0 | 0 | 0 | For |
| State Street | 1,848,951 | 2,416 | 0 | 0 | For |
| T. Rowe Price | 1,263,414 | 0 | 0 | 0 | For |
| Charles Schwab | 808,304 | 0 | 0 | 0 | For |
| ARK Venture Fund | 337,310 | 0 | 0 | 0 | For |
| Equitable | 178,015 | 69,200 | 0 | 0 | Mixed |
| AMERICAN BEACON FUNDS | 223,757 | 0 | 0 | 0 | For |
| TIAA | 221,207 | 0 | 0 | 0 | For |
| American Century | 168,022 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 155,367 | 0 | 0 | 0 | For |
| Brighthouse | 141,865 | 0 | 0 | 0 | For |
| First Trust | 135,021 | 0 | 0 | 0 | For |
| JPMorgan | 128,586 | 0 | 0 | 0 | For |
| ProShares | 95,136 | 0 | 0 | 0 | For |
| Dimensional | 0 | 92,406 | 0 | 0 | Against |
| Lincoln Financial | 84,994 | 3,184 | 0 | 0 | For |
| AIG/SunAmerica | 69,869 | 0 | 0 | 0 | For |
| Russell Investments | 65,283 | 0 | 0 | 0 | For |
| Transamerica | 60,019 | 0 | 0 | 0 | For |
| Global X | 55,500 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 50,397 | 0 | 0 | 0 | For |
| Northern Trust | 44,362 | 0 | 0 | 0 | For |
Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Description as filed by funds: Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2029: John Maraganore, Ph.D.
Beam Therapeutics Inc.’s own tally for this item (“Elect Director: John Maraganore, Ph.D.”): 64,846,080 for, 7,701,591 against, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – The following nominees were elected as Class III directors to serve on the Company's board of directors until the Company's 2029 annual meeting of stockholders, and until his or her successor has been duly elected and qualified, based on the following votes:”
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 68 asset managers below reported 32,468,968 for, 973,349 against, 29,911 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARK ETF Trust | 10,432,026 | 0 | 0 | 0 | For |
| Vanguard | 8,890,898 | 8,333 | 0 | 0 | For |
| Fidelity | 5,159,735 | 0 | 0 | 0 | For |
| BlackRock | 2,218,373 | 0 | 0 | 0 | For |
| State Street | 1,846,785 | 4,582 | 0 | 0 | For |
| T. Rowe Price | 1,263,414 | 0 | 0 | 0 | For |
| Charles Schwab | 808,304 | 0 | 0 | 0 | For |
| ARK Venture Fund | 337,310 | 0 | 0 | 0 | For |
| Equitable | 178,015 | 69,200 | 0 | 0 | Mixed |
| AMERICAN BEACON FUNDS | 223,757 | 0 | 0 | 0 | For |
| TIAA | 221,207 | 0 | 0 | 0 | For |
| American Century | 0 | 168,022 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 155,367 | 0 | 0 | 0 | For |
| Brighthouse | 124,164 | 17,701 | 0 | 0 | Mixed |
| First Trust | 0 | 135,021 | 0 | 0 | Against |
| JPMorgan | 128,586 | 0 | 0 | 0 | For |
| ProShares | 0 | 95,136 | 0 | 0 | Against |
| Dimensional | 0 | 92,406 | 0 | 0 | Against |
| Lincoln Financial | 71,834 | 16,344 | 0 | 0 | Mixed |
| AIG/SunAmerica | 0 | 69,869 | 0 | 0 | Against |
| Russell Investments | 65,283 | 0 | 0 | 0 | For |
| Transamerica | 60,019 | 0 | 0 | 0 | For |
| Global X | 55,500 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 0 | 50,397 | 0 | 0 | Against |
| Northern Trust | 0 | 44,362 | 0 | 0 | Against |
Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
99% Approved · of votes cast
Description as filed by funds: To approve, on an advisory basis, the compensation of our named executive officers.
Beam Therapeutics Inc.’s own tally for this item (“3. Compensation of the Company's named executive officers”): 71,546,749 for, 985,066 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 – The compensation of the Company's named executive officers was approved, on an advisory basis, based on the following votes:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARK ETF Trust | 10,432,026 | 0 | 0 | 0 | For |
| Vanguard | 8,899,230 | 1 | 0 | 0 | For |
| Fidelity | 5,159,735 | 0 | 0 | 0 | For |
| BlackRock | 2,218,373 | 0 | 0 | 0 | For |
| State Street | 1,850,597 | 770 | 0 | 0 | For |
| T. Rowe Price | 1,263,414 | 0 | 0 | 0 | For |
| Charles Schwab | 808,304 | 0 | 0 | 0 | For |
| ARK Venture Fund | 337,310 | 0 | 0 | 0 | For |
| Equitable | 247,215 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 223,757 | 0 | 0 | 0 | For |
| TIAA | 221,207 | 0 | 0 | 0 | For |
| American Century | 0 | 168,022 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 155,367 | 0 | 0 | 0 | For |
| Brighthouse | 141,865 | 0 | 0 | 0 | For |
| First Trust | 135,021 | 0 | 0 | 0 | For |
| JPMorgan | 128,586 | 0 | 0 | 0 | For |
| ProShares | 95,136 | 0 | 0 | 0 | For |
| Dimensional | 92,406 | 0 | 0 | 0 | For |
| Lincoln Financial | 88,178 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 69,869 | 0 | 0 | 0 | For |
| Russell Investments | 65,283 | 0 | 0 | 0 | For |
| Transamerica | 60,019 | 0 | 0 | 0 | For |
| Global X | 55,500 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 50,397 | 0 | 0 | 0 | For |
| Northern Trust | 44,362 | 0 | 0 | 0 | For |
Fund voting reports, all 66 managers: 33,265,328 for, 176,781 against, 29,911 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 8,394,941 | 0 | 0 | 0 | For |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 6,441,267 | 0 | 0 | 0 | For |
| ARCH Venture Management, LLC | 4,540,132 | 0 | 0 | 0 | For |
| Amova Asset Management Co., Ltd. | 3,822,389 | 0 | 0 | 0 | For |
| State Street | 3,057,525 | 20,386 | 0 | 0 | For |
| BlackRock | 2,108,662 | 11,751 | 0 | 0 | For |
| T. Rowe Price | 1,825,963 | 0 | 0 | 0 | For |
| Kynam Capital Management, LP | 0 | 0 | 0 | 1,570,747 | Withhold |
| GEODE CAPITAL MANAGEMENT, LLC | 1,551,483 | 0 | 0 | 0 | For |
| Redmile Group, LLC | 1,164,259 | 0 | 0 | 0 | For |
| Impresa Management LLC | 1,139,443 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 1,000,000 | 0 | 0 | 0 | For |
| Vanguard | 832,834 | 0 | 0 | 0 | For |
| Charles Schwab | 808,940 | 0 | 0 | 0 | For |
| ARK Investment Management LLC | 628,903 | 0 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 570,394 | 0 | 0 | 0 | For |
| Contrarius Group Holdings Ltd | 526,865 | 0 | 0 | 0 | For |
| Northern Trust | 470,989 | 9,721 | 0 | 0 | For |
| ADAR1 Capital Management, LLC | 393,142 | 0 | 0 | 0 | For |
| Two Sigma | 350,318 | 0 | 0 | 0 | For |
| GV Management Company, L.L.C. | 321,603 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 282,584 | 0 | 0 | 0 | For |
| Goldman Sachs | 263,397 | 0 | 0 | 0 | For |
| UBS | 0 | 232,844 | 0 | 0 | Against |
| Nuveen | 232,620 | 0 | 0 | 0 | For |
Institutional-manager reports, all 237 managers: 43,536,247 for, 607,998 against, 1,570,747 withheld, 3,694 abstained, 252 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.8% Approved · of votes cast
Description as filed by funds: RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2026.
Beam Therapeutics Inc.’s own tally for this item (“2. Appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2026”): 85,754,272 for, 165,746 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 – The appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2026 was ratified, based on the following votes:”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 68 asset managers below reported 33,441,548 for, 770 against, 29,911 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARK ETF Trust | 10,432,026 | 0 | 0 | 0 | For |
| Vanguard | 8,899,232 | 0 | 0 | 0 | For |
| Fidelity | 5,159,735 | 0 | 0 | 0 | For |
| BlackRock | 2,218,373 | 0 | 0 | 0 | For |
| State Street | 1,850,597 | 770 | 0 | 0 | For |
| T. Rowe Price | 1,263,414 | 0 | 0 | 0 | For |
| Charles Schwab | 808,304 | 0 | 0 | 0 | For |
| ARK Venture Fund | 337,310 | 0 | 0 | 0 | For |
| Equitable | 247,215 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 223,757 | 0 | 0 | 0 | For |
| TIAA | 221,207 | 0 | 0 | 0 | For |
| American Century | 168,022 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 155,367 | 0 | 0 | 0 | For |
| Brighthouse | 141,865 | 0 | 0 | 0 | For |
| First Trust | 135,021 | 0 | 0 | 0 | For |
| JPMorgan | 128,586 | 0 | 0 | 0 | For |
| ProShares | 95,136 | 0 | 0 | 0 | For |
| Dimensional | 92,406 | 0 | 0 | 0 | For |
| Lincoln Financial | 88,178 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 69,869 | 0 | 0 | 0 | For |
| Russell Investments | 65,283 | 0 | 0 | 0 | For |
| Transamerica | 60,019 | 0 | 0 | 0 | For |
| Global X | 55,500 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 50,397 | 0 | 0 | 0 | For |
| Northern Trust | 44,362 | 0 | 0 | 0 | For |
Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 102,741,848 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | ARK ETF Trust | 10.15% |
| 2 | Vanguard | 8.66% |
| 3 | Fidelity | 5.02% |
| 4 | BlackRock | 2.16% |
| 5 | State Street | 1.80% |
| 6 | T. Rowe Price | 1.23% |
| 7 | Charles Schwab | 0.79% |
| 8 | ARK Venture Fund | 0.33% |
| 9 | Equitable | 0.24% |
| 10 | AMERICAN BEACON FUNDS | 0.22% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 8.17% |
| 2 | FARALLON CAPITAL MANAGEMENT, L.L.C. | 6.27% |
| 3 | ARCH Venture Management, LLC | 4.42% |
| 4 | Amova Asset Management Co., Ltd. | 3.72% |
| 5 | State Street | 3.00% |
| 6 | BlackRock | 2.06% |
| 7 | T. Rowe Price | 1.78% |
| 8 | Kynam Capital Management, LP | 1.53% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.51% |
| 10 | Redmile Group, LLC | 1.13% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| FMR LLC and affiliates | 12,750,369 | 12.41% | Proxy statement (DEF 14A), table as of December 31, 2025 |
| FMR (Fidelity) | 12,452,199 | 12.12% | Form 13F, quarter ended March 31, 2026 |
| Farallon Capital Management, L.L.C. | 10,282,210 | 10.01% | Schedule 13G, filed August 13, 2026 |
| ARK Investment Management LLC | 10,234,862 | 9.96% | Schedule 13G, filed August 14, 2026 |
| Farallon Capital Partners LP and affiliates | 10,141,856 | 9.87% | Proxy statement (DEF 14A), table as of December 31, 2025 |
| Vanguard Group | 9,193,474 | 8.95% | Form 13F, quarter ended March 31, 2026 |
| BlackRock | 8,487,569 | 8.26% | Form 13F, quarter ended March 31, 2026 |
| STATE STREET CORPORATION | 5,228,529 | 5.09% | Schedule 13G, filed February 9, 2026 |
| T. Rowe Price | 2,713,230 | 2.64% | Form 13F, quarter ended March 31, 2026 |
| Dimensional Fund Advisors | 2,154,575 | 2.10% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 102,741,848 shares outstanding, as reported by Beam Therapeutics Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Beam Therapeutics Inc.'s shareholder meeting held June 3, 2026, in the 2025-2026 proxy season, 288 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,534 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers. — Beam Therapeutics Inc.'s filing reports the proposal as approved, with 99% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Beam Therapeutics Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 8, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Beam Therapeutics Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Beam Therapeutics Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Beam Therapeutics (BEAM) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/beam-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.